About Dotter Faculty/Staff Clinical New Techniques Education Research Meetings and Events Contact
HHT Home
Contact Information
HHT Center Physicians
HHT Links
Dr. Chesnutt/PCCM
Dotter Institute

HHT Center of Excellence


Images of Pulmonary AVMs before and after embolization therapy
Pulmonary AVMs A) Before and
B) After embolization therapy.

The Oregon Health & Science University (OHSU) Hereditary Hemorrhagic Telangiectasia Center of Excellence is a multidisciplinary center devoted to the evaluation and treatment of patients with Hereditary Hemorrhagic Telangiectasia (HHT). The OHSU HHT Center includes physicians who are among the most experienced in evaluating and treating patients with HHT and is one of a small group of specialized centers in North America that have been established with the support of the HHT Foundation, International. HHT patients in the Pacific Northwest and other regions of the Western United States can enjoy immediate access to a comprehensive HHT care center.

HHT affects approximately 1 in 5,000 people in the United States. It is a genetic blood vessel disorder characterized by the development of telangiectases, or small arteriovenous malformations (AVMs), which can bleed after only slight trauma. The most common symptoms of HHT is bleeding from the nose. The mouth, tongue, gastrointestinal tract, lungs, skin, and, less frequently, other organs are also involved. Other symptoms of HHT include shortness of breath, fatigue, strokes, transient ischemic attacks (TIAs), brain abscesses, migraine headaches, and chronic anemia. At the OHSU HHT Center, physicians are prepared to evaluate and treat patients with any and all of these problems.

Dr. Mark S. Chesnutt is the director of the OHSU HHT Center. He evaluates all patients with HHT or patients who are suspected of having HHT and coordinates their care.